Abstract
WE wish to announce the launch of a new study called EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly caused by preclinical mitral valve disease [MVD]). EPIC is a global, randomised, double-blinded, parallel group, placebo-controlled study conducted within Good Clinical Practice guidelines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have